WS6 [1421227-53-3]
Referência T2106-5mg
Tamanho : 5mg
Marca : TargetMol
WS6
Copy Product Info
WS6, a β cell proliferation inducer, regulates Erb3 binding protein-1 (EBP1) and the IκB kinase pathway.
Cas No. 1421227-53-3
For research use only—not for human use. No sales to individuals. Use as intended only.
Select Batch
Purity:99.95%
Color:White to Yellow
COA HNMR LCMS
Product Introduction
Bioactivity
Chemical Properties
Storage & Solubility Information
| Description | WS6, a β cell proliferation inducer, regulates Erb3 binding protein-1 (EBP1) and the IκB kinase pathway. |
| Targets & IC50 | Proliferation (β cells):0.28 μM |
| In vitro | In the RIP-DTA mouse model with β-cell ablation, oral administration of WS6 (50 mg/kg) promotes β-cell proliferation, thereby ameliorating diabetes. |
| In vivo | In R7T1 cells (EC50=0.28 μM), WS6 induces cell proliferation through the action on the Erb3 binding protein-1 and IκB kinase signaling pathways. |
| Kinase Assay | PARP assays are conducted in a buffer containing 50 mM Tris (pH 8.0), 1 mM DTT, 1.5 μM [3H]NAD+?(1.6 μCi/mmol), 200 nM biotinylated histone H1, 200 nM slDNA, and 1 nM PARP-1 or 4 nM PARP-2 enzyme. Reactions are terminated with 1.5 mM benzamide, transferred to streptavidin Flash plates, and counted using a TopCount microplate scintillation counter. |
| Cell Research | R7T1 cells are growth-arrested by removal of doxycycline for 2 days and plated into 384-well plates at a density of 3,000 cells/well in growth medium. Β cell proliferation is assessed using CellTiter Glo after 4 days. Fold increase in cell number is calculated by normalizing compound-treated wells to the median of DMSO-treated wells. (Only for Reference) |
| Molecular Weight | 568.59 |
| Formula | C29H31F3N6O3 |
| Cas No. | 1421227-53-3 |
| Smiles | C(C1=C(C(F)(F)F)C=C(NC(CC2=CC=C(OC=3C=C(NC(=O)C4CC4)N=CN3)C=C2)=O)C=C1)N5CCN(C)CC5 |
| Relative Density. | 1.374 g/cm3 (Predicted) |
| Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year Shipping with blue ice/Shipping at ambient temperature. | |||||||||||||||||||||||||||||||||||
| Solubility Information | H2O: < 1 mg/mL (insoluble or slightly soluble) DMSO: 93 mg/mL (163.56 mM), Sonication is recommended. Ethanol: 93 mg/mL (163.56 mM), Sonication is recommended. | |||||||||||||||||||||||||||||||||||
| In Vivo Formulation | 10% DMSO+40% PEG300+5% Tween 80+45% Saline: 3.3 mg/mL (5.8 mM), Sonication is recommended. Please add the solvents sequentially, clarifying the solution as much as possible before adding the next one. Dissolve by heating and/or sonication if necessary. Working solution is recommended to be prepared and used immediately. The formulation provided above is for reference purposes only. In vivo formulations may vary and should be modified based on specific experimental conditions. | |||||||||||||||||||||||||||||||||||
Solution Preparation Table | ||||||||||||||||||||||||||||||||||||
DMSO/Ethanol
Note : The dilution table applies only to solid products. For liquid products, please calculate the stock solution based on the stated concentration and/or density. | ||||||||||||||||||||||||||||||||||||